Treatment Adherence and Clinical Outcomes of Patients with Inflammatory Bowel Disease on Biological Agents During the SARS-CoV-2 Pandemic

[1] Martin Arranz E(2020)Management of COVID-19 pandemic in Spanish inflammatory bowel disease units: results from a national survey Inflamm Bowel Dis 26 1149-1154

[2] Suarez Ferrer C(2020)Review article: prevention, diagnosis and management of COVID-19 in the IBD patient Aliment Pharmacol Ther 52 54-72

[3] García Ramírez L(2020)Potential therapeutic targets and promising drugs for combating SARS-CoV-2 Br J Pharmacol 177 3147-3161

[4] Al-Ani AH(2020)Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry Gastroenterology 159 481.e1-491.e3

[5] Prentice RE(2020)The ENEIDA registry (Nationwide study on genetic and environmental determinants of inflammatory bowel disease) by GETECCU: design, monitoring and functions Gastroenterol Hepatol 43 551-558

[6] Rentsch CA(2020)2019 novel coronavirus disease (COVID-19) in patients with inflammatory bowel diseases Aliment Pharmacol Ther 52 276-283

[7] Zhou H(2020)Incidence, clinical characteristics, and evolution of SARS-Cov-2 infection in patients with inflammatory bowel disease: a single-center study in Madrid, Spain Inflamm Bowel Dis 18 2143-2146

[8] Fang Y(2020)Managing inflammatory bowel disease during COVID-19: summary of recommendations from gastrointestinal societies Clin Gastroenterol Hepatol 5 631-632

[9] Xu T(2020)Views of patients with inflammatory bowel disease on the COVID-19 pandemic: a global survey Lancet Gastroenterol Hepatol 8 775-781

[10] Ni WJ(2020)Inflammatory bowel disease in the COVID-19 pandemic—the patients’ perspective J Crohns Colitis undefined undefined-undefined

[1] Martin Arranz E(2020)Management of COVID-19 pandemic in Spanish inflammatory bowel disease units: results from a national survey Inflamm Bowel Dis 26 1149-1154

[2] Suarez Ferrer C(2020)Review article: prevention, diagnosis and management of COVID-19 in the IBD patient Aliment Pharmacol Ther 52 54-72

[3] García Ramírez L(2020)Potential therapeutic targets and promising drugs for combating SARS-CoV-2 Br J Pharmacol 177 3147-3161

[4] Al-Ani AH(2020)Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry Gastroenterology 159 481.e1-491.e3

[5] Prentice RE(2020)The ENEIDA registry (Nationwide study on genetic and environmental determinants of inflammatory bowel disease) by GETECCU: design, monitoring and functions Gastroenterol Hepatol 43 551-558

[6] Rentsch CA(2020)2019 novel coronavirus disease (COVID-19) in patients with inflammatory bowel diseases Aliment Pharmacol Ther 52 276-283

[7] Zhou H(2020)Incidence, clinical characteristics, and evolution of SARS-Cov-2 infection in patients with inflammatory bowel disease: a single-center study in Madrid, Spain Inflamm Bowel Dis 18 2143-2146

[8] Fang Y(2020)Managing inflammatory bowel disease during COVID-19: summary of recommendations from gastrointestinal societies Clin Gastroenterol Hepatol 5 631-632

[9] Xu T(2020)Views of patients with inflammatory bowel disease on the COVID-19 pandemic: a global survey Lancet Gastroenterol Hepatol 8 775-781

[10] Ni WJ(2020)Inflammatory bowel disease in the COVID-19 pandemic—the patients’ perspective J Crohns Colitis undefined undefined-undefined